Top

Published in:

01-06-2012 | Diagnostic Neuroradiology

MRI and thallium-201 SPECT in the prediction of survival in glioma

Authors: Maaike J. Vos, Johannes Berkhof, Otto S. Hoekstra, Ingeborg Bosma, Eefje M. Sizoo, Jan J. Heimans, Jaap C. Reijneveld, Esther Sanchez, Frank J. Lagerwaard, Jan Buter, David P. Noske, Tjeerd J. Postma

Published in: Neuroradiology | Issue 6/2012

Abstract

Introduction

This paper aims to study the value of MRI and Thallium 201 (²⁰¹Tl) single-photon emission computed tomography (SPECT) in the prediction of overall survival (OS) in glioma patients treated with temozolomide (TMZ) and to evaluate timing of radiological follow-up.

Methods

We included patients treated with TMZ chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM) and with TMZ for recurrent glioma. MRIs and ²⁰¹Tl SPECTs were obtained at regular intervals. The value of both imaging modalities in predicting OS was examined using Cox regression analyses.

Results

Altogether, 138 MRIs and 113 ²⁰¹Tl SPECTs in 46 patients were performed. Both imaging modalities were strongly related to OS (P ≤ 0.02). In newly diagnosed GBM patients, the last follow-up MRI (i.e., after six adjuvant TMZ courses) and SPECT (i.e., after three adjuvant TMZ courses) were the strongest predictors of OS (P = 0.01). In recurrent glioma patients, baseline measurements appeared to be the most predictive of OS (P < 0.01). The addition of one imaging modality to the other did not contribute to the prediction of OS.

Conclusions

Both MRI and ²⁰¹Tl SPECT are valuable in the prediction of OS. It is adequate to restrict to one of both modalities in the radiological follow-up during treatment. In the primary GBM setting, MRI after six adjuvant TMZ courses contributes significantly to the prediction of survival. In the recurrent glioma setting, baseline MRI appears to be a powerful predictor of survival, whereas follow-up MRIs during TMZ seem to be of little additional value.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMed

Vos MJ, Uitdehaag BMJ, Barkhof F et al (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826–830PubMedCrossRef

Cairncross JG, Macdonald DR, Pexman JH, Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38:724–726PubMedCrossRef

Watling CJ, Lee DH, Macdonald DR, Cairncross JG (1994) Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 12:1886–1889PubMed

Cairncross JG, Pexman JH, Rathbone MP, DelMaestro RF (1985) Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17:570–572PubMedCrossRef

Henegar MM, Moran CJ, Silbergeld DL (1996) Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 84:174–179PubMedCrossRef

Ulmer S, Braga TA, Barker FG et al (2006) Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 67:1668–1670PubMedCrossRef

Finn MA, Blumenthal DT, Salzman KL, Jensen RL (2007) Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 67:246–250PubMedCrossRef

Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384PubMed

10.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461PubMedCrossRef

11.

Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410PubMedCrossRef

12.

Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197PubMedCrossRef

13.

Desjardins A, Reardon DA, Herndon JE et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068–7073PubMedCrossRef

14.

Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271–278PubMedCrossRef

15.

van den Bent MJ, Vogelmaum MA, Wen PY, Macdonald DR, Chang SM (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 27:2905–2908PubMedCrossRef

16.

Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729PubMedCrossRef

17.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedCrossRef

18.

Schwartz RB, Carvalho PA, Alexander E III et al (1991) Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. AJNR Am J Neuroradiol 12:1187–1192PubMed

19.

Kosuda S, Fujii H, Aoki S et al (1993) Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors. Ann Nucl Med 7:257–263PubMedCrossRef

20.

Lorberboym M, Mandell LR, Mosesson RE et al (1997) The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 38:223–226PubMed

21.

Vos MJ, Tony BN, Hoekstra OS et al (2007) Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl Med Commun 28:431–439PubMedCrossRef

22.

Roesdi MF, Postma TJ, Hoekstra OS et al (1998) Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 40:251–255PubMedCrossRef

23.

Kallen K, Geijer B, Malmstrom P et al (2000) Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 21:259–267PubMedCrossRef

24.

Vallejos V, Balana C, Fraile M et al (2002) Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 59:81–90PubMedCrossRef

25.

Vos MJ, Hoekstra OS, Barkhof F et al (2003) Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21:3559–3565PubMedCrossRef

26.

Vos MJ, Berkhof J, Postma TJ et al (2006) Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging 33:222–227PubMedCrossRef

27.

Tony B, Vos MJ, Berkhof J et al (2005) Interobserver variability in the semi-quantitative assessment of 201Tl SPECT in cerebral gliomas. Nucl Med Commun 26:45–48PubMedCrossRef

28.

Klein JP, Moeschberger ML (1997) Survival analysis: techniques for censored and truncated data. New York, Springer, pp 271–282

29.

Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394PubMedCrossRef

30.

Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214–221PubMed

31.

Simon JM, Cornu P, Boisserie G et al (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74PubMedCrossRef

32.

Grant R, Walker M, Hadley D et al (2002) Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 57:241–245PubMedCrossRef

33.

Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–766PubMedCrossRef

34.

Bleichner-Perez S, Le Jeune F, Dubois F et al (2007) 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun 28:888–894PubMedCrossRef

35.

Herholtz K, Kracht LW, Heiss WD (2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13:269–271

36.

Hu LS, Baxter LC, Smith KA et al (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 30:552–558PubMedCrossRef

37.

Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554PubMedCrossRef

38.

Leimgruber A, Ostermann S, Yeon EJ et al (2006) Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 64:869–875PubMedCrossRef

39.

Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 238:658–667PubMedCrossRef

40.

Cao Y, Tsien CI, Nagesh V et al (2006) Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 64:876–885PubMedCrossRef

41.

Matsusue E, Fink JR, Rockhill JK et al (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52:297–306PubMedCrossRef

42.

Nowosielski M, Recheis W, Goebel G et al (2011) ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53:291–302PubMedCrossRef

43.

Pope WB, Kim HJ, Huo J et al (2009) Recuurent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Neuroradiology 252:182–189

44.

Rock JP, Scarpace L, Hearshen D et al (2004) Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54:1111–1117PubMedCrossRef

45.

Xu M, See SJ, Ng WH et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919–926PubMed

46.

Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578PubMed

Title: MRI and thallium-201 SPECT in the prediction of survival in glioma
Authors: Maaike J. Vos
Johannes Berkhof
Otto S. Hoekstra
Ingeborg Bosma
Eefje M. Sizoo
Jan J. Heimans
Jaap C. Reijneveld
Esther Sanchez
Frank J. Lagerwaard
Jan Buter
David P. Noske
Tjeerd J. Postma
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Neuroradiology / Issue 6/2012
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-011-0908-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MRI and thallium-201 SPECT in the prediction of survival in glioma

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

MRI and associated clinical characteristics of EV71-induced brainstem encephalitis in children with hand–foot–mouth disease

Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial

Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging

Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited

European Society of Neuroradiology (ESNR)

Correlation of aneurysm occlusion with actual metal coverage at neck after implantation of flow-diverting stent in rabbit models